Metrion Biosciences
The ion channel contract research and drug discovery company in April named Dr. Andrew Southan as the new CEO. He was previously the company’s chief operating officer and first joined Metrion in 2016 as the head of commercial operations.
Southan has more than 25 years of experience in ion channel research and development and has held leadership roles at CeNeS Pharmaceuticals and Ionix Pharmaceuticals. He also worked at BioFocus and Charles River Laboratories.
"My key focus will be to continue the growth of our fee for service business, especially to capitalise on the significant capability we now have for cardiac safety assays and our expanding neuroscience capability," Southan told us.
He also would like the company to establish additional long term FTE-based relationships with clients, similar to its recently signed contract with LifeArc.
"A further key goal will be to use our Innovate UK funding to enhance the dataset for our small molecule Kv1.3 blocker assets and find a partner to develop the lead compounds towards the clinic," he added.
